You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Flumatinib, CML-CP with Ph

Showing 1 - 25 of 2,876
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

Recruiting
  • CML-CP; Mutation;Suboptimal Response or Failure in TKI
  • Wuhan, Hubei, China
    Weiming Li
May 31, 2021

Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

Recruiting
  • MMR on 12 Month
  • Guangzhou, Guangdong, China
  • +1 more
Apr 21, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase

Recruiting
  • CML, Chronic Phase; TKI
  • Flumatinib Mesylate
  • Nilotinib Pill
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 1, 2021

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib

Terminated
Has Results
  • CML
  • +2 more
  • Las Vegas, Nevada
  • +2 more
Apr 28, 2021

Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Radotinib HCl
  • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
  • +17 more
Jan 3, 2022

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

Leukemia, Myeloid, Chronic-Phase Trial in Italy (Nilotinib 300mg BID)

Completed
  • Leukemia, Myeloid, Chronic-Phase
  • Nilotinib 300mg BID
  • Gallarate, Milano, Italy
  • +16 more
Jan 11, 2021

Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Treatment-free Remission
  • TFR(Treatment-Free Remission)
  • (no location specified)
Jun 27, 2022

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia Trial in Worldwide (nilotinib)

Completed
Has Results
  • Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
  • Loma Linda, California
  • +35 more
Mar 25, 2021

Myeloid Leukemia, Philadelphia Positive Trial in Worldwide (Asciminib Pediatric formulation group, Asciminib Adult formulation

Recruiting
  • Myeloid Leukemia, Philadelphia Positive
  • Asciminib Pediatric formulation group
  • Asciminib Adult formulation group
  • Boston, Massachusetts
  • +24 more
Jan 17, 2023

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)

Recruiting
  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
  • Longmont, Colorado
  • +128 more
Aug 1, 2022

Chronic Myelogenous Leukemia - Chronic Phase Trial in United States (Nilotinib)

Terminated
Has Results
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Los Angeles, California
  • +10 more
Jul 26, 2021

Chronic Myelogenous Leukemia Trial in Turkey (Nilotinib)

Completed
Has Results
  • Chronic Myelogenous Leukemia
  • Eskisehir, Meselik, Turkey
  • +12 more
Aug 18, 2020

Chronic Myeloid Leukemia Trial in Worldwide (KRT-232, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia
  • Birmingham, Alabama
  • +25 more
Mar 4, 2022

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Chronic Myeloid Leukemia, Chronic Phase Trial in Beijing (Radotinib, Imatinib)

Active, not recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Beijing, China
    Peking University People's Hospital(北京大学人民医院)
Jan 3, 2022

Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

Recruiting
  • Chronic Myelogenous Leukemia
  • ABL001 40mg BID
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +53 more
Jan 27, 2023

Leukemia Trial in Worldwide (Dasatinib)

Active, not recruiting
Has Results
  • Leukemia
  • Birmingham, Alabama
  • +173 more
Dec 1, 2022

sCD62L and SPARC in Chronic Myeloid Leukemia Patients During

Completed
  • Chronic Myeloid Leukemia
  • ELISA kit
  • Tanta, Egypt
    Tanta University
May 18, 2022